Challenges in Epilepsy Pharmacogenetics
Author Information
Author(s): Sandeep Grover, Meenal Gupta, Ritushree Kukreti
Primary Institution: Institute of Genomics and Integrative Biology (IGIB), Council of Scientific and Industrial Research (CSIR)
Hypothesis
What are the key challenges and recommendations for conducting epidemiological studies in epilepsy pharmacogenetics?
Conclusion
The study highlights the need for consistent study designs and larger sample sizes to improve the reliability of pharmacogenetic research in epilepsy.
Supporting Evidence
- Epilepsy affects approximately 50 million people in India.
- First-generation antiepileptic drugs are commonly used but often lead to adverse drug reactions.
- Genetic variability may explain differences in drug response among epilepsy patients.
Takeaway
Scientists are trying to understand why some epilepsy medicines work for some people but not for others, and they need to study more people to find better answers.
Methodology
The review discusses various methodological issues and recommendations for conducting pharmacogenetic studies in epilepsy.
Potential Biases
Potential biases due to population stratification and confounding factors in study designs.
Limitations
The review notes limitations such as small sample sizes and inconsistencies in phenotypic definitions across studies.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website